Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges to Using Big Data in Cancer.
Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore L, Gawel SH, Grossman RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, Louv B, McGraw D, Meng F, Milgram D, Miller RS, Morgan E, Mukundan L, O'Brien T, Robbins P, Rubin EH, Rubinstein WS, Salmi L, Schaller T, Shi G, Sigman CC, Srivastava S. Sweeney SM, et al. Among authors: hsu k. Cancer Res. 2023 Apr 14;83(8):1175-1182. doi: 10.1158/0008-5472.CAN-22-1274. Cancer Res. 2023. PMID: 36625843 Free PMC article. Review.
Case Studies for Overcoming Challenges in Using Big Data in Cancer.
Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore LD, Gawel SH, Grossman RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, Louv B, McGraw D, Meng F, Milgram D, Miller RS, Morgan E, Mukundan L, O'Brien T, Robbins P, Rubin EH, Rubinstein WS, Salmi L, Schaller TH, Shi G, Sigman CC, Srivastava S. Sweeney SM, et al. Among authors: hsu k. Cancer Res. 2023 Apr 14;83(8):1183-1190. doi: 10.1158/0008-5472.CAN-22-1277. Cancer Res. 2023. PMID: 36625851 Free PMC article. Review.
Antibody-based therapy for solid tumors.
Yan L, Hsu K, Beckman RA. Yan L, et al. Among authors: hsu k. Cancer J. 2008 May-Jun;14(3):178-83. doi: 10.1097/PPO.0b013e318172d71a. Cancer J. 2008. PMID: 18536557 Review.
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Bechter OE, Dumez H, Costermans J, Punie K, Hsu K, Dedieu JF, Ghuysen AF, Francesconi E, Sharma J, Liu L, Schöffski P. Bechter OE, et al. Among authors: hsu k. Cancer Chemother Pharmacol. 2016 Jul;78(1):83-90. doi: 10.1007/s00280-016-3056-0. Epub 2016 May 11. Cancer Chemother Pharmacol. 2016. PMID: 27169794 Clinical Trial.
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E. de Weger VA, et al. Among authors: hsu k. Br J Cancer. 2019 Feb;120(3):286-293. doi: 10.1038/s41416-018-0355-8. Epub 2018 Dec 26. Br J Cancer. 2019. PMID: 30585255 Free PMC article. Clinical Trial.
Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings.
Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei LJ, Hanna M, Ruberg FL, Kittleson M, Kazi D, Dorbala S, Hsu K, Lousada I, Adigun R, Dunnmon P, Kelly J, Gillmore J; Amyloidosis Forum Meeting Panelists. Maurer MS, et al. Among authors: hsu k. Adv Ther. 2024 Jun 4. doi: 10.1007/s12325-024-02891-0. Online ahead of print. Adv Ther. 2024. PMID: 38833142 Review.
2,839 results